Skip to main content
. 2022 Apr 6;14(7):1847. doi: 10.3390/cancers14071847

Figure 3.

Figure 3

Alternative mechanisms for targeting MMP9 lead to enhanced specificity. Starting from the nonspecific small MMP9 inhibitors that chelate zinc ions (e.g., marimastat, ilomastat, and batimastat), through inhibitors targeting other than catalytic domain (N-(4-fluorophenyl)-4-(4-oxo-3,4,5,6,7,8-hexahydroquinazolin-2-ylthio) butanamide; JNJ0966) and ending with function blocking antibodies (REGA 3G12, andecaliximab), which in addition to blocking the activation of MMP9 also inhibit MMP9 activity and substrate binding. The yellow arrow symbolizes increasing specificity of MMP9 inhibitors.